Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.48
TFX's Cash to Debt is ranked lower than
75% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. TFX: 0.48 )
Ranked among companies with meaningful Cash to Debt only.
TFX' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.22 Max: 0.93
Current: 0.48
0.06
0.93
Equity to Asset 0.54
TFX's Equity to Asset is ranked lower than
62% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. TFX: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
TFX' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.48 Max: 0.54
Current: 0.54
0.32
0.54
Interest Coverage 6.69
TFX's Interest Coverage is ranked lower than
82% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. TFX: 6.69 )
Ranked among companies with meaningful Interest Coverage only.
TFX' s Interest Coverage Range Over the Past 10 Years
Min: 2.18  Med: 3.26 Max: 6.69
Current: 6.69
2.18
6.69
F-Score: 8
Z-Score: 3.93
M-Score: -2.70
WACC vs ROIC
9.01%
12.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.99
TFX's Operating margin (%) is ranked higher than
88% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. TFX: 18.99 )
Ranked among companies with meaningful Operating margin (%) only.
TFX' s Operating margin (%) Range Over the Past 10 Years
Min: -6.28  Med: 14.15 Max: 18.99
Current: 18.99
-6.28
18.99
Net-margin (%) 15.09
TFX's Net-margin (%) is ranked higher than
85% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. TFX: 15.09 )
Ranked among companies with meaningful Net-margin (%) only.
TFX' s Net-margin (%) Range Over the Past 10 Years
Min: -12.25  Med: 9.55 Max: 21.66
Current: 15.09
-12.25
21.66
ROE (%) 13.47
TFX's ROE (%) is ranked higher than
78% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. TFX: 13.47 )
Ranked among companies with meaningful ROE (%) only.
TFX' s ROE (%) Range Over the Past 10 Years
Min: -10.11  Med: 11.8 Max: 21.44
Current: 13.47
-10.11
21.44
ROA (%) 7.03
TFX's ROA (%) is ranked higher than
74% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. TFX: 7.03 )
Ranked among companies with meaningful ROA (%) only.
TFX' s ROA (%) Range Over the Past 10 Years
Min: -4.96  Med: 5 Max: 8.55
Current: 7.03
-4.96
8.55
ROC (Joel Greenblatt) (%) 43.24
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. TFX: 43.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TFX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13.25  Med: 30.51 Max: 43.24
Current: 43.24
-13.25
43.24
Revenue Growth (3Y)(%) -0.30
TFX's Revenue Growth (3Y)(%) is ranked lower than
64% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. TFX: -0.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TFX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -11  Med: 2.7 Max: 18.1
Current: -0.3
-11
18.1
» TFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

TFX Guru Trades in Q4 2015

Jim Simons 40,600 sh (New)
Keeley Asset Management Corp 3,170 sh (unchged)
Jerome Dodson Sold Out
Steven Cohen Sold Out
Murray Stahl 4,942 sh (-1.49%)
Chuck Royce 181,800 sh (-12.47%)
Third Avenue Management 45,957 sh (-18.03%)
Joel Greenblatt 85,071 sh (-35.83%)
» More
Q1 2016

TFX Guru Trades in Q1 2016

George Soros 5,800 sh (New)
Paul Tudor Jones 8,620 sh (New)
Jim Simons 154,100 sh (+279.56%)
Keeley Asset Management Corp 5,255 sh (+65.77%)
Chuck Royce 181,800 sh (unchged)
Murray Stahl 4,792 sh (-3.04%)
Third Avenue Management 38,457 sh (-16.32%)
Joel Greenblatt 25,631 sh (-69.87%)
» More
Q2 2016

TFX Guru Trades in Q2 2016

Ron Baron 104,581 sh (New)
Chuck Royce 181,800 sh (unchged)
Keeley Asset Management Corp Sold Out
George Soros Sold Out
Murray Stahl 4,692 sh (-2.09%)
Third Avenue Management 34,743 sh (-9.66%)
Joel Greenblatt 15,179 sh (-40.78%)
Jim Simons 38,800 sh (-74.82%)
Paul Tudor Jones 2,100 sh (-75.64%)
» More
Q3 2016

TFX Guru Trades in Q3 2016

Paul Tudor Jones 4,350 sh (+107.14%)
Chuck Royce 181,800 sh (unchged)
Ron Baron 104,581 sh (unchged)
Murray Stahl 4,385 sh (-6.54%)
Third Avenue Management 23,102 sh (-33.51%)
Jim Simons 17,400 sh (-55.15%)
Joel Greenblatt 6,646 sh (-56.22%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:ALGN, OTCPK:SONVY, OTCPK:CHEOY, NAS:ABMD, NYSE:VAR, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO, NAS:WMGI, NYSE:PEN, NYSE:GMED, OTCPK:NHNKY, NAS:ZLTQ, NAS:BABY, NAS:INGN, OTCPK:IOBCF, NAS:CNMD » details
Traded in other countries:TBH.Germany,
Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Teleflex Inc a Delaware corporation incorporated in 1943. The Company is a provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It markets and sells its products to hospitals and healthcare providers through a combination of its direct sales force and distributors. It manufactures its products at 25 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company operates in following six reportable operating segments: Vascular North America, Anesthesia North America, Surgical North America, EMEA (Europe, Middle East and Africa), Asia and OEM. Vascular North America segment is comprised of North American vascular and interventional access businesses, which offers products that facilitate critical care therapies and other applications. The vascular access products consist of Arrow branded catheters and related devices that are used in procedures, including the administration of intravenous medications and other therapies, the measurement of blood pressure and the withdrawal of blood samples through a single puncture site. The vascular access product portfolio consists of the following products - Arrow Central Venous Catheters; Arrow EZ-IO Intraosseous Vascular Access System; Arrow Peripherally Inserted Central Catheters; Arrow Jugular Axillo-subclavian Central Catheters; VPS G4 Vascular Positioning System; Arrow Arterial Catheterization Sets; and Arrow Percutaneous Sheath Introducers. The interventional access products are used in applications, including dialysis, oncology and critical care therapies. Its interventional access portfolio also includes several Arrow branded products, such as diagnostic and drainage kits, embolectomy balloons, and reinforced percutaneous sheath introducers. Its interventional access products include - Arrow OnControl Powered Bone Marrow / Bone Access System; Arrow Trerotola Percutaneous Thrombectomy Device; Arrow Chronic Hemodialysis Catheters; and Arrow Acute Hemodialysis Catheters. The Anesthesia North America segment is comprised of North American airway management and pain management businesses. The airway management products and related devices consist of - LMA Airways; LMA Atomization; and RUSCH Endotracheal Tubes and Laryngoscopes. The pain management products, which are designed for use in a of surgical and obstetric procedures, consist of - Arrow Epidural Catheters, Needles and Kits; Arrow Peripheral Nerve Block (PNB) Catheters, Pumps, Needles and Kits; AutoFuser Disposable Pain Pumps; and Arrow EZ-IO System. In the Surgical North America the surgical products are designed to provide surgeons with devices for use in sur

Guru Investment Theses on Teleflex Inc

Baron Funds Comments on Teleflex Inc. - Jul 25, 2016

We initiated a position in Teleflex, Inc. (NYSE:TFX), a medical device company that over the past five years has been transformed, under CEO Benson Smith’s leadership, from a diversified industrial company into a pure-play medical device company through a series of divestitures and acquisitions. Today, the company sells products used by hospitals and health care providers for critical care applications and surgical procedures. The company’s products include, among others, catheters that provide vascular access for delivery of intravenous medications, laryngeal masks for delivery of anesthesia, and surgical instruments used for minimally invasive surgery. The company’s products are used in procedures for treatment of acute or life-threatening illnesses and are therefore less susceptible to being cut during an economic downturn.



We think the company has a solid base business that should be able to grow in the mid-single digits on an organic basis driven by volume growth, new product introductions, and to a lesser extent pricing. In addition, we think the company has the potential to accelerate its organic growth through several interesting new product opportunities, including, among others, the Percuvance Surgical System, a surgical instrument for use in minimally invasive procedures. Percuvance requires a smaller incision site than traditional laparoscopic surgery, while maintaining the equivalent rigidity and strength of laparoscopic instruments. Percuvance has the potential to reduce patient trauma and minimize scarring. The company plans to pursue a full market release of the product in the third quarter of 2016. We think the product has widespread application and well over $100 million of revenue potential over the long term.



In addition, the company has several non-revenue dependent margin expansion initiatives in place, including manufacturing plant consolidation, acquisitions of distributors, and material substitution. New product launches at higher margins should also drive margin expansion. We think the combination of organic growth and margin expansion should drive low double-digit earnings growth, with potential for faster earnings growth if new products accelerate the revenue growth rate or management executes accretive acquisitions.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Top Ranked Articles about Teleflex Inc

Baron Funds Comments on Teleflex Inc. Guru stock highlight
We initiated a position in Teleflex, Inc. (NYSE:TFX), a medical device company that over the past five years has been transformed, under CEO Benson Smith’s leadership, from a diversified industrial company into a pure-play medical device company through a series of divestitures and acquisitions. Today, the company sells products used by hospitals and health care providers for critical care applications and surgical procedures. The company’s products include, among others, catheters that provide vascular access for delivery of intravenous medications, laryngeal masks for delivery of anesthesia, and surgical instruments used for minimally invasive surgery. The company’s products are used in procedures for treatment of acute or life-threatening illnesses and are therefore less susceptible to being cut during an economic downturn. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.02
TFX's P/E(ttm) is ranked lower than
53% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. TFX: 27.02 )
Ranked among companies with meaningful P/E(ttm) only.
TFX' s P/E(ttm) Range Over the Past 10 Years
Min: 4.99  Med: 18.95 Max: 39.52
Current: 27.02
4.99
39.52
Forward P/E 18.83
TFX's Forward P/E is ranked higher than
70% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. TFX: 18.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.08
TFX's PE(NRI) is ranked lower than
53% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. TFX: 28.08 )
Ranked among companies with meaningful PE(NRI) only.
TFX' s PE(NRI) Range Over the Past 10 Years
Min: 13.97  Med: 25.8 Max: 64.93
Current: 28.08
13.97
64.93
Price/Owner Earnings (ttm) 20.65
TFX's Price/Owner Earnings (ttm) is ranked higher than
71% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 30.39 vs. TFX: 20.65 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TFX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.84  Med: 14.62 Max: 47.82
Current: 20.65
5.84
47.82
P/B 3.31
TFX's P/B is ranked lower than
53% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. TFX: 3.31 )
Ranked among companies with meaningful P/B only.
TFX' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 1.85 Max: 3.94
Current: 3.31
1.04
3.94
P/S 4.09
TFX's P/S is ranked lower than
62% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. TFX: 4.09 )
Ranked among companies with meaningful P/S only.
TFX' s P/S Range Over the Past 10 Years
Min: 0.71  Med: 1.7 Max: 4.83
Current: 4.09
0.71
4.83
PFCF 19.86
TFX's PFCF is ranked higher than
65% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. TFX: 19.86 )
Ranked among companies with meaningful PFCF only.
TFX' s PFCF Range Over the Past 10 Years
Min: 5.91  Med: 15.98 Max: 51.54
Current: 19.86
5.91
51.54
POCF 17.48
TFX's POCF is ranked higher than
54% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. TFX: 17.48 )
Ranked among companies with meaningful POCF only.
TFX' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 13.18 Max: 27.22
Current: 17.48
5.22
27.22
EV-to-EBIT 22.51
TFX's EV-to-EBIT is ranked lower than
53% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. TFX: 22.51 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.1  Med: 16.8 Max: 28.8
Current: 22.51
-40.1
28.8
EV-to-EBITDA 16.62
TFX's EV-to-EBITDA is ranked higher than
50% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. TFX: 16.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
TFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.3  Med: 11.55 Max: 3794.7
Current: 16.62
-371.3
3794.7
Shiller P/E 36.29
TFX's Shiller P/E is ranked higher than
61% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. TFX: 36.29 )
Ranked among companies with meaningful Shiller P/E only.
TFX' s Shiller P/E Range Over the Past 10 Years
Min: 10.92  Med: 20.44 Max: 42.96
Current: 36.29
10.92
42.96
Current Ratio 2.57
TFX's Current Ratio is ranked higher than
53% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. TFX: 2.57 )
Ranked among companies with meaningful Current Ratio only.
TFX' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.99 Max: 5.2
Current: 2.57
1.46
5.2
Quick Ratio 1.82
TFX's Quick Ratio is ranked higher than
51% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. TFX: 1.82 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.26 Max: 4.01
Current: 1.82
0.86
4.01
Days Inventory 144.73
TFX's Days Inventory is ranked lower than
56% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. TFX: 144.73 )
Ranked among companies with meaningful Days Inventory only.
TFX' s Days Inventory Range Over the Past 10 Years
Min: 121.53  Med: 140.15 Max: 171.38
Current: 144.73
121.53
171.38
Days Sales Outstanding 51.98
TFX's Days Sales Outstanding is ranked higher than
72% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. TFX: 51.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.98  Med: 64.04 Max: 81.26
Current: 51.98
51.98
81.26
Days Payable 29.98
TFX's Days Payable is ranked lower than
78% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. TFX: 29.98 )
Ranked among companies with meaningful Days Payable only.
TFX' s Days Payable Range Over the Past 10 Years
Min: 26.07  Med: 34.53 Max: 69.62
Current: 29.98
26.07
69.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.87
TFX's Dividend Yield is ranked lower than
70% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. TFX: 0.87 )
Ranked among companies with meaningful Dividend Yield only.
TFX' s Dividend Yield Range Over the Past 10 Years
Min: 0.73  Med: 1.82 Max: 3.48
Current: 0.87
0.73
3.48
Dividend Payout 0.24
TFX's Dividend Payout is ranked higher than
79% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. TFX: 0.24 )
Ranked among companies with meaningful Dividend Payout only.
TFX' s Dividend Payout Range Over the Past 10 Years
Min: 0.17  Med: 0.29 Max: 1.26
Current: 0.24
0.17
1.26
Forward Dividend Yield 0.88
TFX's Forward Dividend Yield is ranked lower than
75% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. TFX: 0.88 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.87
TFX's Yield on cost (5-Year) is ranked lower than
74% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. TFX: 0.87 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TFX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.73  Med: 1.82 Max: 3.48
Current: 0.87
0.73
3.48
3-Year Average Share Buyback Ratio -0.50
TFX's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. TFX: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TFX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -1 Max: 0.8
Current: -0.5
-2.1
0.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.10
TFX's Price/Projected FCF is ranked lower than
53% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. TFX: 2.10 )
Ranked among companies with meaningful Price/Projected FCF only.
TFX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.14 Max: 2.88
Current: 2.1
0.47
2.88
Price/Median PS Value 2.40
TFX's Price/Median PS Value is ranked lower than
91% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. TFX: 2.40 )
Ranked among companies with meaningful Price/Median PS Value only.
TFX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 0.71 Max: 2.75
Current: 2.4
0.42
2.75
Earnings Yield (Greenblatt) (%) 4.43
TFX's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. TFX: 4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TFX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.5  Med: 5.65 Max: 9.4
Current: 4.43
3.5
9.4
Forward Rate of Return (Yacktman) (%) 1.56
TFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
70% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. TFX: 1.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TFX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.56  Med: 6.5 Max: 19.1
Current: 1.56
1.56
19.1

More Statistics

Revenue (TTM) (Mil) $1,839
EPS (TTM) $ 5.80
Beta0.96
Short Percentage of Float5.06%
52-Week Range $125.28 - 188.79
Shares Outstanding (Mil)44.05

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) 6.99 8.20
EPS w/o NRI ($) 6.99 8.20
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Teleflex Inc. Jul 25 2016 
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Blog Coverage Teleflex Set to Acquire Vascular Solutions Dec 05 2016
VASCULAR SOLUTIONS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti,... Dec 03 2016
TELEFLEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Dec 02 2016
Teleflex Incorporated -- Moody's affirms Teleflex's Ba2 CFR on news of Vascular Solutions... Dec 02 2016
Teleflex To Acquire Vascular Solutions for $1B (TFX) Dec 02 2016
Should You Avoid Everest Re Group Ltd (RE)? Dec 02 2016
Stock Futures Hold Lower After U.S. Adds 178,000 Jobs Dec 02 2016
Medical Device Companies Vascular Solutions, Teleflex Agree to $1 Billion Merger Dec 02 2016
Vascular to be bought by Teleflex in a $1 billion deal Dec 02 2016
Vascular Solutions to be Acquired by Teleflex Incorporated Dec 02 2016
Teleflex Incorporated to Acquire Vascular Solutions Dec 02 2016
Investors Are Clamoring For Teleflex Incorporated (TFX) Nov 26 2016
Moving Average Crossover Alert: Teleflex (TFX) Nov 22 2016
Teleflex to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 16 2016
TELEFLEX INC Financials Nov 01 2016
ETF’s with exposure to Teleflex, Inc. : October 31, 2016 Oct 31 2016
Teleflex, Inc. :TFX-US: Earnings Analysis: Q3, 2016 By the Numbers : October 28, 2016 Oct 28 2016
Teleflex Incorporated Signs New Agreement with Premier Inc. for Implantable Infusion Ports Oct 28 2016
Teleflex Incorporated Signs New Agreement with Premier Inc. for Implantable Infusion Ports Oct 28 2016
Edited Transcript of TFX earnings conference call or presentation 27-Oct-16 12:00pm GMT Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)